Kamada

Developer of life saving therapeutics.

Maya TradingView

Market view

Stock chart

Coverage

Analyses on Kamada (7)

June 9, 2026
June 9, 2026
1. Almada Has Realized a Holding, Kamada and Matricelf Still Need Capacity to Become Revenue or a Trial
  The recent biotech filings should be ranked by milestone quality: Almada has completed an exit with a clear proceeds path, Kamada received regulatory testing capacity, Matricelf advanced into engineering runs, and Compugen mainly provided investor framing.
  +2
May 13, 2026
May 13, 2026
1. Follow-up
  Kamada follow-up: San Antonio shifts the plasma test to customers and price
  San Antonio approval closes the near-term regulatory checkpoint, but it shifts Kamada's plasma test to price, customers and collection. Without NSP contracts and visible collection economics, the approval is execution progress, not yet a proven model change.
2. Kamada in the first quarter: San Antonio is approved, but the cash test is still ahead
  Kamada preserved its 2026 growth story in the first quarter, but it did not resolve the cash test: San Antonio is now approved and guidance stayed intact, while gross margin declined, operating cash flow was slightly negative, and the April dividend reduces the flexibility visib…

Same sector

More companies in Biotechnology (15)